GlassScriptPhysician profile
Rajesh U Bhakta
NPI 1023077872
$5,844.23
in general payments reported to CMS, 2019-2025
36 companies · $753 in 2025
The $753 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,584 · 2020: $1,935 · 2021: $30.89 · 2022: $139 · 2023: $260 · 2024: $142 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $807.73 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $653.30 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $522.86 | 2019-2022 | |
| Medtronic, INC. | $473.95 | 2025 | Symplicity G3, Protege Rx |
| Allergan, INC. | $339.18 | 2019-2020 | |
| Boston Scientific Corporation | $288.49 | 2021-2025 | Watchman Flx |
| Pfizer INC. | $268.78 | 2019-2020 | |
| Astellas Pharma US INC | $258.09 | 2019 | |
| Lilly USA, LLC | $244.36 | 2019-2020 | |
| Novo Nordisk INC | $212.13 | 2019-2020 | |
| Glaxosmithkline, LLC. | $209.64 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.67 | 2019-2020 | |
| Madrigal Pharmaceuticals | $144.15 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $138.20 | 2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $119.48 | 2019-2020 | |
| Amarin Pharma, INC. | $110.79 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $102.33 | 2019-2020 | |
| Sanofi Pasteur INC. | $90.53 | 2019 | |
| Abbott Laboratories | $83.52 | 2019-2020 | |
| Abbvie INC. | $53.38 | 2020 | |
| Merck Sharp & Dohme LLC | $47.45 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $43.15 | 2019 | |
| Eisai INC. | $42.18 | 2020 | |
| Ironwood Pharmaceuticals, INC | $40.54 | 2020 | |
| Radius Health, INC. | $35.38 | 2020 | |
| Lifescan, INC. | $24.15 | 2019 | |
| Ge Healthcare | $20.48 | 2019 | |
| Mannkind Corporation | $16.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.42 | 2019 | |
| Scilex Pharmaceuticals INC. | $15.14 | 2019 | |
| Corcept Therapeutics | $14.78 | 2019 | |
| Mdd US Operations, LLC | $13.99 | 2019 | |
| Phadia US INC. | $13.98 | 2020 | |
| Medtronic USA, INC. | $13.93 | 2019 | |
| Hikma Pharmaceuticals USA | $13.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Bhakta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.